Catalyst
Slingshot members are tracking this event:
TAGRISSO (osimertinib) receives positive CHMP opinion for patients with EGFR T790M mutation-positive metastatic non-small cell lung cancer
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| AZN |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 18, 2015
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Chmp, Metastatic Non-small Cell Lung Cancer, Egfr, T790m, Tagrisso, Osimertinib, Nsclc, Azd9291
